Genetics of Lupus

| Written by Kevin Facun

DESCRIPTION

The IP provides for a simple genetic testing method, either sequencing or using a probe-based platform, which involves the determination of the association of selected single nucleotide polymorphisms (SNPs) that are correlated with the risk of Systemic lupus erythematosus (SLE). Potentially, this IP is useful in the setting of preventive measures and monitoring, screening and treatment of early conditions, verification of suspected cases, and genetic counseling and genetic testing.

 

VALUE PROPOSITION

  • Capable of detecting potential risk to Lupus
  • Provides for a simple genetic testing method
  • It may be used as a sole basis due to high confidence level
  • Serve as an efficient determination means for individuals who are at-risk in developing Lupus

 

MARKET APPLICATIONS AND COMMERCIAL OPPORTUNITIES

  • There is a tendency for familial aggregation with a higher frequency of disease among first-degree relatives.
  • There are 20% to 50%  concordance rates of monozygotic twins and 5% of dizygotic twins.
  • There’s a 30 times higher risk for siblings of affected individuals than that for the general population.

 

DEVELOPMENT STATUS

The IP is ready for further research and development

 

IP STATUS

Patent Application Filed

 

TYPE OF PARTNERSHIP BEING SOUGHT

  • Licensing. We are looking for IP licensees interested in expanding their line of products
  • Co-Investment/Co-Funding. We are looking for partners and co-investors to fund further studies for further development